Details
Stereochemistry | RACEMIC |
Molecular Formula | C8H18NO2 |
Molecular Weight | 160.2343 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 1 |
SHOW SMILES / InChI
SMILES
CC(C[N+](C)(C)C)OC(=O)C
InChI
InChIKey=NZWOPGCLSHLLPA-UHFFFAOYSA-N
InChI=1S/C8H18NO2/c1-7(11-8(2)10)6-9(3,4)5/h7H,6H2,1-5H3/q+1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17565027Curator's Comment:: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019193s013lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/9622546
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17565027
Curator's Comment:: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019193s013lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/9622546
Methacholine (trade name Provocholine) is a synthetic choline ester that acts as a muscarinic receptor agonist. Methacholine is primarily used to diagnose bronchial hyperreactivity, which is the hallmark of asthma and also occurs in chronic obstructive pulmonary disease. This is accomplished through the bronchial challenge test, or methacholine challenge, in which a subject inhales aerosolized methacholine, leading to bronchoconstriction.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL245 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9622546 |
|||
Target ID: CHEMBL211 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9622546 |
59.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | PROVOCHOLINE Approved UseProvocholine® (methacholine chloride powder for inhalation) is indicated for the diagnosis of bronchial airway hyperreactivity in subjects who do not have clinically apparent asthma. Launch Date5.31100795E11 |
Doses
Dose | Population | Adverse events |
---|---|---|
16 mg/mL 5 times / day multiple, respiratory (max) Recommended Dose: 16 mg/mL, 5 times / day Route: respiratory Route: multiple Dose: 16 mg/mL, 5 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Bronchial airway hyperreactivity Sources: Page: p.1 |
Disc. AE: Bronchoconstriction... AEs leading to discontinuation/dose reduction: Bronchoconstriction (severe) Sources: Page: p.1 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Bronchoconstriction | severe Disc. AE |
16 mg/mL 5 times / day multiple, respiratory (max) Recommended Dose: 16 mg/mL, 5 times / day Route: respiratory Route: multiple Dose: 16 mg/mL, 5 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Bronchial airway hyperreactivity Sources: Page: p.1 |
PubMed
Title | Date | PubMed |
---|---|---|
Noninvasive method to measure airway obstruction in nonanesthetized allergen-sensitized and challenged mice. | 2001 |
|
Bronchoconstrictor reactivity to NKA in allergic dogs: a comparison to histamine and methacholine. | 2001 |
|
The effect of acute alteration in oxygen tension on the bronchodilator response to salbutamol in vitro and in vivo in man. | 2001 |
|
Effect of the cyclooxygenase-2 inhibitor celecoxib on bronchial responsiveness and cough reflex sensitivity in asthmatics. | 2001 |
|
Airway foreign body with clinical features mimicking bronchial asthma. | 2001 |
|
Bronchial hyperresponsiveness and exhaled nitric oxide in patients with cardiac disease. | 2001 |
|
Changes in indices of airway hyperresponsiveness during one year of treatment with inhaled corticosteroids in patients with asthma. | 2001 Apr |
|
Increased frequency of Chlamydia pneumoniae antibodies in patients with asthma. | 2001 Apr |
|
Glucocorticoid treatment increases inhibitory m(2) muscarinic receptor expression and function in the airways. | 2001 Apr |
|
Conditioned medium from hypoxic cytotrophoblasts alters arterial function. | 2001 Apr |
|
Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity. | 2001 Apr |
|
Tumour necrosis factor-alpha: the role of this multifunctional cytokine in asthma. | 2001 Apr |
|
Gibbs sampling-based segregation analysis of asthma-associated quantitative traits in a population-based sample of nuclear families. | 2001 Apr |
|
Changes in airway resistance by simultaneous exposure to TNF-alpha and IL-1beta in perfused rat lungs. | 2001 Apr |
|
Hexachlorobenzene-induced eosinophilic and granulomatous lung inflammation is associated with in vivo airways hyperresponsiveness in the Brown Norway rat. | 2001 Apr 1 |
|
Enhanced airway Th2 response after allergen challenge in mice deficient in CC chemokine receptor-2 (CCR2). | 2001 Apr 15 |
|
Respiratory effects of a single dive to 50 meters in sport divers with asymptomatic respiratory atopy. | 2001 Feb |
|
G(q/11) and G(i/o) activation profiles in CHO cells expressing human muscarinic acetylcholine receptors: dependence on agonist as well as receptor-subtype. | 2001 Feb |
|
The lack of the bronchoprotective and not the bronchodilatory ability of deep inspiration is associated with airway hyperresponsiveness. | 2001 Feb |
|
Protective effects of volatile agents against methacholine-induced bronchoconstriction in rats. | 2001 Feb |
|
Blockade of eosinophil migration and airway hyperresponsiveness by cPLA2-inhibition. | 2001 Feb |
|
Coronary and laryngeal spasm provoked by methacholine inhalation. | 2001 Feb |
|
Regular inhaled salbutamol : effect on airway responsiveness to methacholine and adenosine 5'-monophosphate and tolerance to bronchoprotection. | 2001 Feb |
|
Oilseed rape flour: another allergen causing occupational asthma among farmers. | 2001 Feb |
|
ATS guidelines for methacholine and exercise challenge testing. | 2001 Jan |
|
Acute anti-inflammatory effects of inhaled budesonide in asthma: a randomized controlled trial. | 2001 Jan |
|
Abnormal responses to endothelial agonists in Raynaud's phenomenon and scleroderma. | 2001 Jan |
|
Linkage between bronchial responsiveness to methacholine and gene markers of IL-4 cytokine gene cluster and T-cell receptor alpha/delta gene complex in Korean nuclear families. | 2001 Jan |
|
[Asthma related to inhalation of Plantago ovata]. | 2001 Jan 13 |
|
Seasonal variability of non-specific bronchial responsiveness in asthmatic patients with allergy to house dust mites. | 2001 Jan-Feb |
|
Airways hyperresponsiveness and the effects of lung inflation. | 2001 Jan-Mar |
|
Correlation between airway hyperresponsiveness and airway inflammation in a young adult population: eosinophil, ECP, and cytokine levels in induced sputum. | 2001 Mar |
|
Airway responses to a diluent used in the methacholine challenge test. | 2001 Mar |
|
High-resolution computed tomographic evaluation of airway distensibility and the effects of lung inflation on airway caliber in healthy subjects and individuals with asthma. | 2001 Mar |
|
Measurements of resistance by the interrupter technique and of transcutaneous partial pressure of oxygen in young children during methacholine challenge. | 2001 Mar |
|
Effect of salmeterol on allergen-induced airway inflammation in mild allergic asthma. | 2001 Mar |
|
The transcription factor early growth-response factor 1 modulates tumor necrosis factor-alpha, immunoglobulin E, and airway responsiveness in mice. | 2001 Mar |
|
Temporal association between airway hyperresponsiveness and airway eosinophilia in ovalbumin-sensitized mice. | 2001 Mar |
|
Drug treatment of airway inflammation in asthma. | 2001 Mar |
|
Airway administration of Escherichia coli endotoxin to mice induces glucocorticosteroid-resistant bronchoconstriction and vasopermeation. | 2001 Mar |
|
Inhibition of eosinophilic inflammation in allergen-challenged TNF receptor p55/p75--and TNF receptor p55-deficient mice. | 2001 Mar |
|
Methacholine challenge testing in Reserve Officer Training Corps cadets. | 2001 Mar |
|
Relationship between bronchial hyperresponsiveness and development of asthma in wheezy infants. | 2001 Mar |
|
Enhanced production of leukotrienes by peripheral leukocytes and specific IgE antibodies in patients with chronic obstructive pulmonary disease. | 2001 Mar |
|
A comparison of ovariectomy models for estrogen studies. | 2001 Mar |
|
Muscarinic depression of synaptic transmission in the epileptogenic GABA withdrawal syndrome focus. | 2001 May |
|
Airway inflammation and bronchial hyperresponsiveness after Mycoplasma pneumoniae infection in a murine model. | 2001 May |
|
Eosinophil markers in blood, serum, and urine for monitoring the clinical course in childhood asthma: impact of budesonide treatment and withdrawal. | 2001 May |
|
Mutation screening of the muscarinic M(2) and M(3) receptor genes in normal and asthmatic subjects. | 2001 May |
|
Endothelial function during stimulation of renin-angiotensin system by low-sodium diet in humans. | 2001 May |
Patents
Sample Use Guides
Provocholine is inhaled using a standardized procedure. The challenge is performed by giving a subject ascending serial concentrations of Provocholine. At each concentration, five breaths are administered by a nebulizer that permits intermittent delivery time of 0.6 seconds by a breath-actuated timing device (dosimeter). At each of five inhalations of a serial concentration, the subject begins at functional residual capacity (FRC) and slowly and completely inhales the dose delivered. Within 5 minutes, FEV1 values are determined. The procedure ends either when there is a 20% or greater reduction in the FEV1 compared with the baseline sodium chloride solution value (i.e., a positive response) or if 188.88 total cumulative units have been administered and the FEV1 has been reduced by 14 % or less (i.e., a negative response). If there is a reduction of 15% to 19% in the FEV, compared with baseline, either the challenge may be repeated at that concentration or a higher concentration may be given as long as the dosage administered does not result in total cumulative units exceeding 188.88.
Route of Administration:
Respiratory
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9622546
Agonist activity of methacholine was determined using assay of accumulation of [3H]inositol monophosphate. The CHO cells were labeled in 12-well plates with 1 uCi/mL myo-[3H]inositol for 24 h. Wells contained ca. 3* 10^5 cells in a volume of 1 mL. Cells were then washed once with Hank’s balanced salt media containing 20 mM HEPES buffer (pH 7.4) and were then incubated in the buffered Hank’s media containing 10 mM LiCl at room temperature for 15 min. Muscarinic agents were then added to each well. After incubation for 1 h at 37 °C, the medium was aspirated and replaced with 750 uL of cold 20 mM aqueous formic acid. After 35 min at 4 °C, the formic acid was removed and replaced with 250 uL of 60 mM NH4OH. The inositol monophosphate in the NH4OH solution was isolated by anionexchange chromatography19 and counted for tritium in Hydrofluor scintillation fluid. Cells were treated with 0.001 - 10 uM of methacholine, EC50 was determined to be 120 nM.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175369
Created by
admin on Sat Jun 26 06:56:45 UTC 2021 , Edited by admin on Sat Jun 26 06:56:45 UTC 2021
|
||
|
NCI_THESAURUS |
C1937
Created by
admin on Sat Jun 26 06:56:45 UTC 2021 , Edited by admin on Sat Jun 26 06:56:45 UTC 2021
|
||
|
NDF-RT |
N0000175884
Created by
admin on Sat Jun 26 06:56:45 UTC 2021 , Edited by admin on Sat Jun 26 06:56:45 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
7438
Created by
admin on Sat Jun 26 06:56:45 UTC 2021 , Edited by admin on Sat Jun 26 06:56:45 UTC 2021
|
PRIMARY | |||
|
METHACHOLINE
Created by
admin on Sat Jun 26 06:56:45 UTC 2021 , Edited by admin on Sat Jun 26 06:56:45 UTC 2021
|
PRIMARY | |||
|
155080
Created by
admin on Sat Jun 26 06:56:45 UTC 2021 , Edited by admin on Sat Jun 26 06:56:45 UTC 2021
|
PRIMARY | RxNorm | ||
|
55-92-5
Created by
admin on Sat Jun 26 06:56:45 UTC 2021 , Edited by admin on Sat Jun 26 06:56:45 UTC 2021
|
PRIMARY | |||
|
55-92-5
Created by
admin on Sat Jun 26 06:56:45 UTC 2021 , Edited by admin on Sat Jun 26 06:56:45 UTC 2021
|
PRIMARY | |||
|
DB06709
Created by
admin on Sat Jun 26 06:56:45 UTC 2021 , Edited by admin on Sat Jun 26 06:56:45 UTC 2021
|
PRIMARY | |||
|
C61837
Created by
admin on Sat Jun 26 06:56:45 UTC 2021 , Edited by admin on Sat Jun 26 06:56:45 UTC 2021
|
PRIMARY | |||
|
03V657ZD3V
Created by
admin on Sat Jun 26 06:56:45 UTC 2021 , Edited by admin on Sat Jun 26 06:56:45 UTC 2021
|
PRIMARY | |||
|
SUB03201MIG
Created by
admin on Sat Jun 26 06:56:45 UTC 2021 , Edited by admin on Sat Jun 26 06:56:45 UTC 2021
|
PRIMARY | |||
|
1726
Created by
admin on Sat Jun 26 06:56:45 UTC 2021 , Edited by admin on Sat Jun 26 06:56:45 UTC 2021
|
PRIMARY | |||
|
1993
Created by
admin on Sat Jun 26 06:56:45 UTC 2021 , Edited by admin on Sat Jun 26 06:56:45 UTC 2021
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)